Skip to main navigation menu Skip to main content Skip to site footer
Plant Science Today (PST)

Research Articles

Early Access

Beneficial influences of Amorphophallus konjac k. koch in counteracting weight gain resulting from a high-fat diet and the use of antipsychotic drugs

DOI
https://doi.org/10.14719/pst.7700
Submitted
12 February 2025
Published
27-10-2025
Versions

Abstract

Obesity and overweight represent a significant challenge to global health, necessitating immediate action to create safe and effective treatment options. This research aimed to evaluate the effectiveness of Amorphophallus konjac K. Koch (konjac) as a natural anti-obesity agent in mice that developed obesity due to a high-fat diet and olanzapine treatment. After administering A. konjac in the form of konjac flour orally to mice over eight weeks, we measured body weight gain, total body fat and visceral fat mass, along with the serum lipid profile. The study also focused on evaluating hepatic steatosis and liver injury. Konjac flour was shown to inhibit weight gain and reduce BMI in obese mice. Notably, the groups treated with konjac powder exhibited significant reductions in visceral fat mass compared to the untreated obese group. Moreover, the oral administration of konjac powder led to marked improvements in serum lipid levels and mitigated liver damage by decreasing fat accumulation in the liver and lowering aspartate aminotransferase activity. Research involving Amorphophallus konjac K. Koch (konjac) revealed its significant weight loss effects in obese mice fed a high-fat diet combined with olanzapine. These outcomes suggest that this herbal formulation could be a valuable addition to anti-obesity therapies, helping to prevent the accumulation of body fat and influence lipid metabolism.  

References

  1. 1. World Health Organization. Obesity and overweight fact sheet. 2024. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
  2. 2. Ansari S, Haboubi H, Haboubi N. Adult obesity complications: challenges and clinical impact. Ther Adv Endocrinol Metab. 2020;11:2042018820934955. https://doi.org/10.1177/2042018820934955
  3. 3. Ruban A, Stoenchev K, Ashrafian H, Teare J. Current treatments for obesity. Clin Med (Lond). 2019;19:205-12. https://doi.org/10.7861/clinmedicine.19-3-205
  4. 4. Aziz MA, Millat MS, Akter T, Hossain MS, Islam MM, Mohsin S, et al. A comprehensive review on clinically proven medicinal plants in the treatment of overweight and obesity, with mechanistic insights. Heliyon. 2023;9(2):e13493. https://doi.org/10.1016/j.heliyon.2023.e13493
  5. 5. Jain A, Sarsaiya S, Gong Q, Wu Q, Shi J. Amorphophallus konjac: traditional uses, bioactive potential and emerging health applications. Front Plant Sci. 2025;16:1530814. https://doi.org/10.3389/fpls.2025.1530814
  6. 6. Behera S, Ray R. Nutritional and potential health benefits of konjac glucomannan, a promising polysaccharide of elephant foot yam, Amorphophallus konjac K. Koch: review. Food Rev Int. 2016;33(1):22-43. https://doi.org/10.1080/87559129.2015.1137310
  7. 7. Devaraj RD, Reddy CK, Xu B. Health-promoting effects of konjac glucomannan and its practical applications: a critical review. Int J Biol Macromol. 2019;126:273-81. https://doi.org/10.1016/j.ijbiomac.2018.12.203
  8. 8. Mah E, Chen O, Liska DJ, Blumberg JB. Dietary supplements for weight management: a narrative review of safety and metabolic health benefits. Nutrients. 2022;14(9):1787. https://doi.org/10.3390/nu14091787
  9. 9. National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the care and use of laboratory animals. 8th ed. Washington (DC): National Academies Press (US); 2011. https://doi.org/10.17226/12910
  10. 10. Shertzer HG, Kendig EL, Nasrallah HA, Johansson E, Genter MB. Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole. Int J Obes (Lond). 2010;34(6):970-9. https://doi.org/10.1038/ijo.2009.291
  11. 11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
  12. 12. Karimpour Reyhan S, Yadegar A, Samimi S, Nakhaei P, Esteghamati A, Nakhjavani M, et al. Atherogenic index of plasma (AIP): the most accurate indicator of overweight and obesity among lipid indices in type 2 diabetes-findings from a cross-sectional study. Endocrinol Diabetes Metab. 2024;7(6):e70007. https://doi.org/10.1002/edm2.70007
  13. 13. Martins T, Castro-Ribeiro C, Lemos S, Ferreira T, Nascimento-Gonçalves E, Rosa E, et al. Murine models of obesity. Obesities. 2022;2(2):127-47. https://doi.org/10.3390/obesities2020012
  14. 14. Slaoui M, Bauchet AL, Fiette L. Tissue sampling and processing for histopathology evaluation. Methods Mol Biol. 2017;1641:101-14. https://doi.org/10.1007/978-1-4939-7172-5_4
  15. 15. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology. 2003;28 Suppl 1:83-96. https://doi.org/10.1016/S0306-4530(02)00114-2
  16. 16. Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61:111-61. https://doi.org/10.2165/00003495-200161010-00011
  17. 17. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012;122:253-70. https://doi.org/10.1042/CS20110386
  18. 18. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacol. 2010;35:1520-30. https://doi.org/10.1038/npp.2010.21
  19. 19. Kumar GC, Sarala N, Reddy MM, Manjunath H. Effect of metformin on olanzapine-induced weight gain: a 12-week randomised open-label study. J Clin Sci. 2025;22(1):11-7. https://doi.org/10.4103/jcls.jcls_62_24
  20. 20. Hiluy JC, Nazar BP, Gonçalves WS, et al. Effectiveness of pharmacologic interventions in the management of weight gain in patients with severe mental illness: a systematic review and meta-analysis. Prim Care Companion CNS Disord. 2019;21(6):19r02483. https://doi.org/10.4088/PCC.19r02483
  21. 21. Singh R, Bansal Y, Sodhi RK, Singh DP, Bishnoi M, Kondepudi KK, et al. Berberine attenuated olanzapine-induced metabolic alterations in mice: targeting transient receptor potential vanilloid type 1 and 3 channels. Life Sci. 2020;247:117442. https://doi.org/10.1016/j.lfs.2020.117442
  22. 22. Woods SE, Genter MB, Shertzer HG. A comparison of the effectiveness of metformin and acetaminophen in preventing olanzapine toxicity in mice. Pharmacologia. 2012;3(7):233-8. https://doi.org/10.5567/pharmacologia.2012.233.238
  23. 23. Kim J, Lee N, Suh SB, Jang S, Kim S, Kim DG, et al. Metformin ameliorates olanzapine-induced disturbances in POMC neuron number, axonal projection and hypothalamic leptin resistance. BMB Rep. 2022;55(6):293-8. https://doi.org/10.5483/BMBRep.2022.55.6.026
  24. 24. Keithley J, Swanson B. Glucomannan and obesity: a critical review. Altern Ther Health Med. 2005;11(6):30-4.
  25. 25. Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27-31. https://doi.org/10.4103/0976-0105.177703
  26. 26. Poobalan AS, Aucott LS, Smith WCS, Avenell A, Jung R, Broom J. Long-term weight loss effects on all cause mortality in overweight/obese populations. Obes Rev. 2007;8:503-13. https://doi.org/10.1111/j.1467-789X.2007.00393.x
  27. 27. Aoe S, Kudo H, Sakurai S. Effects of liquid konjac on parameters related to obesity in diet-induced obese mice. Biosci Biotechnol Biochem. 2015;79:1141-6. https://doi.org/10.1080/09168451.2015.1018119
  28. 28. Keithley JK, Swanson B, Mikolaitis SL, DeMeo M, Zeller JM, Fogg L, et al. Safety and efficacy of glucomannan for weight loss in overweight and moderately obese adults. J Obes. 2013;2013:610908. https://doi.org/10.1155/2013/610908
  29. 29. Ministry of Health, Vietnam. Guidelines for diagnostic and treatment of obesity. Issued with Decision No. 2892/QD-BYT. 2022.
  30. 30. Zhang MY, Huang CY, Wang X, Hong JR, Peng SS. The effect of foods containing refined konjac meal on human lipid metabolism. Biomed Environ Sci. 1990;3:99-105.
  31. 31. Arvill A, Bodin L. Effect of short-term ingestion of konjac glucomannan on serum cholesterol in healthy men. Am J Clin Nutr. 1995;61:585-9. https://doi.org/10.1093/ajcn/61.3.585
  32. 32. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic and clinical implications. Hepatology. 2010;51(2):679-89.

Downloads

Download data is not yet available.